ADMA Biologics Gets FDA OK for Increased IVIG Production Scale

 ADMA Increases Total Forecasted Plant Manufacturing Capacity from 400,000 Liters up to 600,000 Liters and Increases Total Forecasted Peak Revenues in Excess of $300 Million

Enhanced Gross Margins and Cost Efficiencies Expected to be Realized Beginning Late 2021 and Accelerate Throughout 2022 on Path to Profitability

https://finance.yahoo.com/news/adma-biologics-receives-fda-approval-110000496.html